Who we are

Upon injury or infection, prokaryotic and/or eukaryotic cells release plethora of disorganized denatured molecules into tissue microenvironment.

Many of them are water-insoluble, that clog capillaries, incur damages of cellular membrane and disturb tissue homeostasis.

The water-insoluble molecules in living organisms need to be removed as soon as they appear in tissues.

If not, they cause deleterious inflammation.

Hydrophobicity : an ancient damage-associated molecular pattern that initiates innate immune responses SY Seong, P Matzinger - Nature Review Immunology, 2004

In the beginning, life on earth was created in the water.

The battle between water-soluble and insoluble substances began
when the lives advanced to the land.

Water-insoluble molecules are the origin of foe.

The immune system has piggy-backed on the system devastating
water-insoluble aggregates.

We study immunology and inflammation, taking biological solubility
at the center of intricate immunological balance.

What we do

New Approach to Inflammatory Diseases (Small Molecule)

  • Based on deep understanding of DAMPs (Damage Associated Molecular Patterns)
  • Targeting multi-modal, complex inflammatory diseases
  • Developing immune modulating molecules with strong efficacy and excellent safety profiles

Next Generation NanoMAb® Technology

  • Based on a wide array of nanobody libraries from immunized camelid
  • Focusing on new antigen targets
  • Developing nanobody-based cancer therapeutics with high affinity and low immunogenicity

From bispecific nanobodies to genetically conjugated Nanotoxin®

  • High-throughput cell line development
  • Targeted integration into hot-spot chromatin structure
  • Multi-targeting with stable protein structure


Seung-Yong Seong, M.D., Ph.D.
Founder and Chief Executive Officer
  • Seoul National University, College of Medicine, M.D., Ph.D.
  • Professor, Chair of Microbiology and Immunology, Seoul National University, College of Medicine
  • Director(former), Wide River Institute of Immunology, Seoul National University
  • Chief Editor, World Journal of Immunology
  • Major publications as a corresponding author ‘Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune response’
    (Nature Reviews Immunology, 2004)
    ‘Multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy’ (Nature Nanotechnology, 2011)
Seon-Ae Han, Ph.D.
Chief Technology Officer & Chief Development Officer / Global R&D Center
  • University of Tokyo, College of Pharmacy, Ph.D.
  • Ewha Woman’s University, College of Pharmacy, MSc.
  • Managing Director of R&D Center, Sinsin Pharmaceutical Co., Ltd.
  • Director, new drug development, Reyon Phamaceutical Co., Ltd.
  • General manager, regulatory affairs and drug development, Bukwang Pharmaceutical Co., Ltd.
  • Senior manager, drug development, Dongwha Pharmaceutical Co., Ltd.
  • Principal research scientist, Mogam Biotechnology Research Institute
Jeong-Tae Kim, MBA
Chief Operating Officer
  • University of Michigan, Ann Arbor, MBA
  • Yonsei University, BA
  • CEO, SK Plasma Co., Ltd.
  • VP, business development/strategic planning/licensing, SK Chemicals Life Science
  • CEO, SK Eurochem
  • Senior consultant, Ernst & Young Consulting Co.
  • Manager, international business, Kolon International Co.
Jung-Seob Kim, Ph.D.
Head of Nanobody Research
  • Seoul National University, Interdisciplinary Program of Agricultural Biotechnology, Ph.D.
  • Seoul National University, College of Agricultural Chemistry, MSc.
  • Senior manager, cell line engineering/R&D planning, GC Pharma
  • Adjunct professor, Department of Biotechnology, The Catholic University of Korea
  • Chief researcher, rare disease/protein engineering, Mogam Institute for Biomedical Research
Song-Jin Lee, Ph.D.
Head of R&D Planning & Small Molecule Research
  • Seoul National University, College of Pharmacy, Ph.D.
  • Kangwon National University, College of Pharmacy, MSc.
  • Senior manager, technology transfer & manufacturing oversight, CJ Healthcare
  • Head of drug evaluation center, CJ Cheiljedang
  • Senior manager, clinical development/R&D strategy, YUHAN
Sang-Beum Lee, Ph.D.
Chief Scientist
  • Gangneung-wonju National University, molecular biology, Ph.D.
  • University of Hawaii at Manoa, Post-Doc.
  • Wide River Institute of Immunology, Seoul National University, Post-Doc.
Hyun-Mi Park, Ph.D.
Principal Researcher
  • Kangwon National University, Biological Sciences, Biochemistry, Ph.D.
  • Wide River Institute of Immunology, Seoul National University, Post-Doc.
Hoi-Kwon Jung
Chief Financial Officer
  • Sogang University, Business Administration
  • Certified Public Accountant (KICPA)
  • Director, business management, Huayi Brothers Korea Co., Ltd.
  • Manager, IPO department, Hyundai Securities Co., Ltd.
  • Accountant, Assurance department, EY Hanyoung Assurance

Getting together